http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

the use of metoclopramide tablets is recommended for adults only therapy should not exceed 12 weeks in duration symptomatic gastroesophageal reflux metoclopramide tablets are indicated as short term 4 to 12 weeks therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms if symptoms are confined to particular situations such as following the evening meal use of metoclopramide as single doses prior to the provocative situation should be considered rather than using the drug throughout the day healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q i d as there is no documented correlation between symptoms and healing of esophageal lesions patients with documented lesions should be monitored endoscopically diabetic gastroparesis diabetic gastric stasis metoclopramide tablets are indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis the usual manifestations of delayed gastric emptying e g nausea vomiting heartburn persistent fullness after meals and anorexia appear to respond to metoclopramide within different time intervals significant relief of nausea occurs early and continues to improve over a three week period relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_8534 DOID_8534

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB01233 drugbank:DB01233

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-21T08:07:59.502Z

http://purl.org/np/RAZBNExVLj... RAZBNExVLj

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-21T08:07:59.502Z